U.S. regulator approves Teva migraine drug, shares rise

Shares of Israeli drugmaker Teva Pharmaceutical Industries rose over 5 percent in after-hours trading on Friday after the U.S. Food and Drug Administration (FDA) approved the company’s new migraine treatment, a drug Teva has been banking on to help revive its fortunes.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *